Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

NCT00783692
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

NCT02728726
View directory record Official record
Conditions
General Surgery
Interventions
Sugammadex, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 15, 2026, 8:37 AM EDT
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
View directory record Official record
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

Gentamicin Bladder Instillation in Individuals With Spinal Cord Injury Having Chronic Urinary Tract Infections

NCT03931408
View directory record Official record
Conditions
Neurogenic Bladder, Spinal Cord Injuries
Interventions
Gentamicin Sulfate, Placebo instillation (saline alone), No instillation
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 15, 2026, 8:37 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

NCT01516255
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, moxifloxacin, electrocardiogram (ECG)
Drug · Procedure
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

NCT02347176
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
24
States / cities
Phoenix, Arizona • Rogers, Arkansas • Fremont, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 15, 2026, 8:37 AM EDT
Withdrawn Phase 2 Interventional

Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children

NCT01561508
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
gamma-amino-butyric acid, Xylitol
Drug · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Not applicable Interventional Results available

Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System

NCT04341948
View directory record Official record
Conditions
Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty, Partial Knee Replacement
Interventions
SPRINT Peripheral Nerve Stimulation (PNS) System
Device
Lead sponsor
SPR Therapeutics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Little Rock, Arkansas • San Diego, California • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

NCT05014438
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
BMS-986166, Branebrutinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Fremont, California • Brandon, Florida • Coral Gables, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)

NCT00933543
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Visonac PDT (MAL PDT), Vehicle cream (placebo), PDT
Drug · Procedure
Lead sponsor
Photocure
Industry
Eligibility
9 Years to 35 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Naperville, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 15, 2026, 8:37 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized, Double-Blind Study to Assess the Effect of a Postbiotic on Oxidative Stress and Exercise Performance

NCT06795425
View directory record Official record
Conditions
Oxidative Stress, Healthy, Exercise-induced Muscle Damage, Exercise-induced Muscle Soreness, Immune Function, Gut Health, Microbiome Analysis, Exercise Performance, Exercise Metabolism
Interventions
Postbiotic Active Lifestyle Blend, Placebo
Dietary Supplement · Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Not applicable Interventional Results available

Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper

NCT02737826
View directory record Official record
Conditions
Chronic Pain, Opioid Pain Medication
Interventions
Buprenorphine Initiation - Phase I, Gabapentin + Buprenorphine - Phase II, Placebo + Buprenorphine - Phase II, Buprenorphine taper - Phase II
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

NCT04166058
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Functional Constipation
Interventions
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

NCT01584648
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Trametinib placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

StaphVAX in Cardiovascular Surgery Patients

NCT00211913
View directory record Official record
Conditions
Staphylococcal Infections, Cardiovascular Diseases, Cardiovascular Surgical Procedures
Interventions
S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate, placebo
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 15, 2026, 8:37 AM EDT
Recruiting Phase 2 Interventional

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933
View directory record Official record
Conditions
Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Interventions
HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
Drug
Lead sponsor
Hoth Therapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Irvine, California • Orange, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

NCT04440176
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 14 Years
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
20
States / cities
Mobile, Alabama • San Diego, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Incontinence Without Memory Problems

NCT02436889
View directory record Official record
Conditions
Urge Incontinence, Urinary Incontinence, Urge
Interventions
Mirabegron, Tolterodine Tartrate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 15, 2026, 8:37 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

RESTOR: PK/PD mTORi Inhibition in Older Adults

NCT06658093
View directory record Official record
Conditions
Aging
Interventions
Rapamycin, Everolimus, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 90 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD3293 Thorough QT Study in Healthy Male Volunteers

NCT02040987
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AZD3293, Placebo, Moxifloxacin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 15, 2026, 8:37 AM EDT
Terminated Phase 1 Interventional

Ketamine and Magnesium in Post-operative Pain Control in Patients Treated With Opioids

NCT02940509
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine plus Magnesium sulfate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 15, 2026, 8:37 AM EDT
Recruiting Phase 3 Interventional

Brexanolone Lifting Outcomes Of Moms

NCT07822321
View directory record Official record
Conditions
Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression, Post-Natal Depression, Peripartum Depression
Interventions
LPCN 1154A, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
15 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Tucson, Arizona • Canoga Park, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 8:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing

NCT00713349
View directory record Official record
Conditions
Wounds
Interventions
Xenaderm Vehicle, Placebo comparator
Drug · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Oct 15, 2026, 8:37 AM EDT